The New England Journal of Medicine  has published a phase III clinical trial showing that a B cell targeting monoclonal antibody, ianalumab, was effective in more than half of the patients with primary immune thrombocytopenia (ITP).  Moreover, treatment maintained safe platelet counts without serious bleeding episodes for at least one year. 

In rheumatology, we're no stranger to uncertainty. In any diagnosis of seronegative rheumatoid arthritis, it's always our invitation to reconsider the diagnosis. 

Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.